Location of Repository

Fixed-dose combination for adults accessing antiretroviral therapy

By SA HIV Clinicians Society

Abstract

This document serves to guide clinicians and programme managers on how to switch from 3 separate antiretroviral (ARV) drugs to the new, single, fixed-dose combination (FDC) tablet containing tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV). \ud \ud Summary\ud Transitioning from individual drugs to an FDC tablet needs to be managed carefully, particularly regarding stock management, ordering processes, supply-chain integrity and comprehensive patient counselling. \ud \ud Priority groups\ud • Initially, FDC supply will be insufficient to provide for all FDC-suitable patients\ud • Therefore, the National Department of Health (NDoH) has recommended that the following patient groups be prioritized for FDC initiation/switch:\ud • Priority group 1: All HIV-positive patients newly initiating ART – adults, adolescents and pregnant women (regardless of CD4 count (amendment to the guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) anticipated in April 2013) – and who do not have contra-indications to the FDC component drugs \ud • Priority group 2: HIV-positive pregnant women and breastfeeding mothers currently stable on lamivudine (3TC), TDF and EFV\ud • Priority group 3: Virologically suppressed patients on a stavudine (d4T)-based regimen and who have normal renal function\ud • Priority group 4: Stable patients receiving individual TDF, 3TC and EFV and who have tuberculosis (TB) co-infection\ud • Priority group 5: Stable patients receiving individual TDF, 3TC and EFV and who have other co-morbidites (e.g. hypertension, diabetes)\ud • Priority group 6: Patients receiving individual TDF, 3TC and EFV and who request to switch to the FDC treatment\ud • Priority group 7: Patients receiving individual TDF, 3TC and EFV and who, after counselling, agree to switch to the FDC treatment.\ud \ud Important: Clinic staff must co-ordinate this process and only switch as many patients to the FDC tablet as stock allows. This should avoid patients being switched back and forth between FDC and individual drugs due to insufficient stock.\ud \ud Note: The FDC tablet is not significantly larger than EFV or lopinavir/ritonavir (LOP/r) (Aluvia); therefore, swallowing should not be problematic.\ud \ud S Afr J HIV Med 2013;14(1 Suppl):41-43. DOI:10.7196/SAJHIVMED.91

Topics: Public aspects of medicine, RA1-1270
Publisher: AOSIS
Year: 2013
DOI identifier: 10.7196/SAJHIVMED.913
OAI identifier: oai:doaj.org/article:8e24738d9d5c4a6c88d66090504b40eb
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/2078-6751 (external link)
  • https://doaj.org/toc/1608-9693 (external link)
  • http://www.sajhivmed.org.za/in... (external link)
  • https://doaj.org/article/8e247... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.